Metabolic coupling in phyllodes tumor of the breast and its association with tumor progression

Kim,Nah Ihm; Park,Min Ho; Kweon,Sun-Seog; Lee,Ji Shin

doi:10.3892/ol.2023.14132

Metabolic coupling in phyllodes tumor of the breast and its association with tumor progression

Authors:
- Nah Ihm Kim
- Min Ho Park
- Sun-Seog Kweon
- Ji Shin Lee
View Affiliations

Affiliations: Department of Pathology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea, Department of Surgery, Chonnam National University Medical School, Gwangju 61469, Republic of Korea, Department of Preventive Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea
Published online on: November 3, 2023 https://doi.org/10.3892/ol.2023.14132
Article Number: 545
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are markers of metabolic coupling in breast cancer. Loss of caveolin‑1 (Cav‑1) and upregulation of monocarboxylate transporters (MCTs), especially MCT1 and MCT4, serve an important role in metabolic coupling necessary for release and uptake of metabolites. However, the occurrence of these phenomena in phyllodes tumors (PTs) of the breast is unclear. A total of 101 PTs (60 benign, 26 borderline and 15 malignant) and nine breast tissue samples with no pathological lesions were analyzed. Immunohistochemical staining for Cav‑1, MCT1 and MCT4 was performed using tissue microarray and their expression in both stromal and epithelial components was assessed. Cav‑1 expression in PTs demonstrated a significant decrease in the stromal component compared with that in the normal breast tissues (P<0.001). MCT1 expression in both epithelial and stromal components was significantly increased in PTs, compared with that in normal breast tissues (both P<0.001). Stromal MCT1 and MCT4 expression were different depending on tumor grade of PTs, and stromal MCT1 expression significantly increased with increasing tumor grade (P<0.001). Although not statistically significant, stromal Cav‑1 expression notably decreased with increases in PT grade. High stromal MCT1 expression was significantly associated with lower disease‑free survival rate in comparison with low stromal MCT1 expression (P<0.05). These results suggested that changes in protein expression of Cav‑1, MCT1 and MCT4 may be associated with tumorigenesis and progression of PTs of the breast.

View Figures

View References

1	Allison KH, Brogi E, Ellis IO, Fox SB, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt SJ, et al: World Health Organization classification of tumours editorial board. Breast tumors. 5th edition. IARC Press; Lyon: 2019
2	Hoda SA, Brogi E, Koerner FC and Rosen PP: Rosen's Breast Pathology. 4th edition. Lippincott Williams & Wilkins; Philadelphia, PA: 2014
3	Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, Sangalli C, Catania C, Toffalorio F, Noberasco C, et al: Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 88:427–436. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zeng S, Zhang X, Yang D, Wang X and Ren G: Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Mol Clin Oncol. 3:663–671. 2015. View Article : Google Scholar : PubMed/NCBI
5	Fede ÂBS, Pereira Souza R, Doi M, De Brot M, Aparecida Bueno de Toledo Osorio C, Rocha Melo Gondim G, Casali-da-Rocha JC, Jbili R, Bitencourt AGV, Alves de Souza J, et al: Malignant pyllodes tumor of the breast: A practice review. Clin Pract. 11:205–215. 2021. View Article : Google Scholar : PubMed/NCBI
6	Yu J and Kansal K: Management of Stromal Lesions. Surg Clin North Am. 102:1017–1030. 2022. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 44:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
9	Penkert J, Ripperger T, Schieck M, Schlegelberger B, Steinemann D and Illig T: On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer. Oncotarget. 7:67626–67649. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sun X, Wang M, Wang M, Yao L, Li X, Dong H, Li M, Sun T, Liu X, Liu Y and Xu Y: Role of proton-coupled monocarboxylate transporters in cancer: From metabolic crosstalk to therapeutic potential. Front Cell Dev Biol. 8:6512020. View Article : Google Scholar : PubMed/NCBI
11	Stine ZE, Schug ZT, Salvino JM and Dang CV: Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 21:141–162. 2022. View Article : Google Scholar : PubMed/NCBI
12	Mostafavi S, Zalpoor H and Hassan ZM: The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. Cell Mol Biol Lett. 27:582022. View Article : Google Scholar : PubMed/NCBI
13	Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F and Baltazar F: Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology. 56:860–867. 2010. View Article : Google Scholar : PubMed/NCBI
14	Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F and Lisanti MP: Using the ‘reverse Warburg effect’ to identify high-risk breast cancer patients: Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 11:1108–1117. 2012. View Article : Google Scholar : PubMed/NCBI
15	Martins D, Beça FF, Sousa B, Baltazar F, Paredes J and Schmitt F: Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma. Cell Cycle. 12:2684–2690. 2013. View Article : Google Scholar : PubMed/NCBI
16	Johnson JM, Cotzia P, Fratamico R, Mikkilineni L, Chen J, Colombo D, Mollaee M, Whitaker-Menezes D, Domingo-Vidal M, Lin Z, et al: MCT1 in invasive ductal carcinoma: Monocarboxylate metabolism and aggressive breast cancer. Front Cell Dev Biol. 5:272017. View Article : Google Scholar : PubMed/NCBI
17	Yeong J, Thike AA, Ikeda M, Lim JCT, Lee B, Nakamura S, Iqbal J and Tan PH: Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. J Clin Pathol. 71:161–167. 2018. View Article : Google Scholar : PubMed/NCBI
18	Xiao S, Zhu H, Shi Y, Wu Z, Wu H and Xie M: Prognostic and predictive value of monocarboxylate transporter 4 in patients with breast cancer. Oncol Lett. 20:2143–2152. 2020. View Article : Google Scholar : PubMed/NCBI
19	Agelopoulos K, Kersting C, Korsching E, Schmidt H, Kuijper A, August C, Wülfing P, Tio J, Boecker W, van Diest PJ, et al: Egfr amplification specific gene expression in phyllodes tumours of the breast. Cell Oncol. 29:443–451. 2007.PubMed/NCBI
20	Kwon JE, Jung WH and Koo JS: The expression of metabolism-related proteins in phyllodes tumors. Tumour Biol. 34:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
21	Kim GE, Kim JH, Lee KH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Park MH and Yoon JH: Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors. Appl Immunohistochem Mol Morphol. 20:298–303. 2012. View Article : Google Scholar : PubMed/NCBI
22	Payen VL, Mina E, Van Hée VF, Porporato PE and Sonveaux P: Monocarboxylate transporters in cancer. Mol Metab. 33:48–66. 2020. View Article : Google Scholar : PubMed/NCBI
23	Parton RG, McMahon KA and Wu Y: Caveolae: Formation, dynamics, and function. Curr Opin Cell Biol. 65:8–16. 2020. View Article : Google Scholar : PubMed/NCBI
24	Williams TM and Lisanti MP: The Caveolin genes: From cell biology to medicine. Ann Med. 36:584–595. 2004. View Article : Google Scholar : PubMed/NCBI
25	Zhang Z, Gao Z, Rajthala S, Sapkota D, Dongre H, Parajuli H, Suliman S, Das R, Li L, Bindoff LA, et al: Metabolic reprogramming of normal oral fibroblasts correlated with increased glycolytic metabolism of oral squamous cell carcinoma and precedes their activation into carcinoma associated fibroblasts. Cell Mol Life Sci. 77:1115–1133. 2020. View Article : Google Scholar : PubMed/NCBI
26	Pinheiro C, Penna V, Morais-Santos F, Abrahão-Machado LF, Ribeiro G, Curcelli EC, Olivieri MV, Morini S, Valença I, Ribeiro D, et al: Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: Distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med. 12:1182014. View Article : Google Scholar : PubMed/NCBI
27	Jensen DH, Therkildsen MH and Dabelsteen E: A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts. J Oral Pathol Med. 44:714–721. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM and Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol. 158:833–839. 2001. View Article : Google Scholar : PubMed/NCBI